文献速递冠心病

无心力衰竭或心室功能不全的急性心肌梗死患者使用β受体阻滞剂与死亡率的关系

β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

本研究基于英国和威尔士国家注册数据,纳入179,810例无心力衰竭或左心室收缩功能不全的急性心肌梗死住院存活患者,采用倾向评分加权和工具变量分析,发现β受体阻滞剂使用与1年死亡率无显著关联,校正后平均治疗效应系数为0.07(95%CI:-0.60至0.75;P=0.827)。

要点

  • 在无心力衰竭或左心室收缩功能不全的急性心肌梗死存活患者中,β受体阻滞剂使用与1年死亡率无显著关联。
  • 未校正的1年死亡率在接收β受体阻滞剂的患者中较低(4.9% vs 11.2%;P<0.001),但校正后差异无统计学意义。
  • ST段抬高型心肌梗死和非ST段抬高型心肌梗死亚组的结果相似。

核心结论

  • 在无心力衰竭或左心室收缩功能不全的急性心肌梗死住院存活患者中,β受体阻滞剂使用与1年内任何时间点的死亡风险降低无关。

研究设计与样本

  • 采用生存时间逆概率加权倾向评分和工具变量分析,研究β受体阻滞剂使用与1年死亡率之间的关联。

主要发现

  • 在91,895例ST段抬高型心肌梗死患者中,88,542例(96.4%)接受β受体阻滞剂;在87,915例非ST段抬高型心肌梗死患者中,81,933例(93.2%)接受β受体阻滞剂。
  • 整个队列观察人年数超过163,772,共有9,373例死亡(5.2%)。
  • 未校正的1年死亡率在接收β受体阻滞剂的患者中低于未接收者(4.9% vs 11.2%;P<0.001)。
  • 加权和校正后,β受体阻滞剂使用与否的死亡率无显著差异(平均治疗效应系数:0.07;95%CI:-0.60至0.75;P=0.827)。
  • ST段抬高型心肌梗死(平均治疗效应系数:0.30;95%CI:-0.98至1.58;P=0.637)和非ST段抬高型心肌梗死(平均治疗效应系数:-0.07;95%CI:-0.68至0.54;P=0.819)的结果相似。

临床怎么用

  • 对于无心力衰竭或左心室收缩功能不全的急性心肌梗死住院存活患者,β受体阻滞剂使用与1年死亡率无显著关联,临床决策需综合考虑。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For acute myocardial infarction (AMI) without heart failure (HF), it is unclear if β-blockers are associated with reduced mortality. OBJECTIVES: The goal of this study was to determine the association between β-blocker use and mortality in patients with AMI without HF or left ventricular systolic dysfunction (LVSD). METHODS: This cohort study used national English and Welsh registry data from the Myocardial Ischaemia National Audit Project. A total of 179,810 survivors of hospitalization with AMI without HF or LVSD, between January 1, 2007, and June 30, 2013 (final follow-up: December 31, 2013), were assessed. Survival-time inverse probability weighting propensity scores and instrumental variable analyses were used to investigate the association between the use of β-blockers and 1-year mortality. RESULTS: Of 91,895 patients with ST-segment elevation myocardial infarction and 87,915 patients with non-ST-segment elevation myocardial infarction, 88,542 (96.4%) and 81,933 (93.2%) received β-blockers, respectively. For the entire cohort, with >163,772 person-years of observation, there were 9,373 deaths (5.2%). Unadjusted 1-year mortality was lower for patients who received β-blockers compared with those who did not (4.9% vs. 11.2%; p < 0.001). However, after weighting and adjustment, there was no significant difference in mortality between those with and without β-blocker use (average treatment effect [ATE] coefficient: 0.07; 95% confidence interval [CI]: -0.60 to 0.75; p = 0.827). Findings were similar for ST-segment elevation myocardial infarction (ATE coefficient: 0.30; 95% CI: -0.98 to 1.58; p = 0.637) and non-ST-segment elevation myocardial infarction (ATE coefficient: -0.07; 95% CI: -0.68 to 0.54; p = 0.819). CONCLUSIONS: Among survivors of hospitalization with AMI who did not have HF or LVSD as recorded in the hospital, the use of β-blockers was not associated with a lower risk of death at any time point up to 1 year. (β-Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure; NCT02786654).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Dondo TB, Hall M, West RM, et al. β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J Am Coll Cardiol. 2017. PMID: 28571635. doi:10.1016/j.jacc.2017.03.578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。